Related Articles
Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis
The application of immunotherapy combined with taxanes in second‑line treatment of advanced HER2 negative gastric cancer
Irinotecan plus raltitrexed as second‑line chemotherapy for metastatic colorectal cancer: A retrospective study
Efficacy of lapatinib combined with capecitabine in patients with HER2‑positive metastatic breast cancer in a real‑world study